[12] Patent
[11] Patent No.:GC0007616  
[45] Date of Publishing the Grant of the Patent: 30/Apr /2018                48/2018  
Number of the Decision to Grant the Patent:2018/126220
Date of the Decision to Grant the Patent:19/Apr/2018

[21] Application No.:GC 2010-26357

[22] Filing Date:6/12/2010

[30] Priority:

[33] State [32] Priority date [31] Priority No.
US
7/12/2009
61/267,155

[72] Inventors:1- Joerg Berghausen،2- Frank Stowasser،3- Prasad Koteswara Kapa،4- Joseph Mckenna،5- Joel Slade،6- Raeann Wu،7- Zhengming Du

[73] Owner: Novartis AG, Lichtstrasse 35 4056, Basel , Switzerland

[74] Agent: Saud M. A. Shawwaf Law Office

  

 

  

[51]IPC:
Int. Cl.7: A61k31/506 , A61p35/00

[56] Cited Documents:

-WO 2006000420 A1 (NOVARTIS AG [CH];NOVARTIS PHARMA GMBH [AT]; IRM LLC; DINGQIANG [US];) 5 January 2006
-WO 2007071752 A2 (NOVARTIS AG [CH];NOVARTIS PHARMA GMBH [AT]; BOLD GUIDO[CH]; FURET PA) 28 June 2007
 
Examiner: PH. Mohammad S. AlMousa

[54] CRYSTALLINE FORMS OF 3-2,6-DICHLORO-3,5-DIMETHOXY-PHENYL-1-{6-[4-4-ETHYL-PIPERAZIN-1-YL-PHENYLAMINO]-PYRIMIDIN-4-YL}-1-METHYL-UREA AND SALTS THEREOF
[57] Abstract: [0110] The present technology provides novel anhydrous and hydrated crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea, amorphous and anhydrous crystalline polymorphs of its monophosphoric acid salt, and the hydrochloride salt, including its dihydrate. The present technology further provides methods for preparing the various forms, compositions containing them, and methods of treatment employing them.
No. of claims: 15     No. of figures: 9


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.